Dr. Agarwal’s Health Care Ltd. (DAHCL) has raised US$80 Mn from existing investors TPG Growth (the middle market and growth equity platform of leading global alternative asset management firm, TPG) and Temasek, (a global investment company headquartered in Singapore). The fundraise will provide significant capital to fuel the company’s expansion plans. The company plans to deploy capital to expand the current network of 150+ centres to over 300+ centres in the next 3 years. Along with the expansion of the network, the company will also be investing in technological advancements for vision correction such as SMILE, Laser Cataract Surgery and for advanced technologies to treat Vitreo-retinal diseases such as Diabetic Retinopathy and Age-related macular degeneration.
Prof. (Dr.) Amar Agarwal, Chairman, Dr. Agarwal’s Group of Eye Hospitals said, “Backing from investors such as TPG and Temasek, further affirms our faith in staying true to our vision of being a truly global healthcare organization.The new investments will be used to expand our Indian and International footprint, along with acquiring the latest technologies for super-specialty eyecare.”
“We continue to be excited about the growth potential of the company and share the company’s vision of providing world class clinical outcomes along with compelling financial performance. Dr. Agarwal’s has the potential to become the global leader in eye care segment,” said Ankur Thadani, Business Unit Partner in TPG Growth.
Dr. Adil Agarwal, CEO, Dr. Agarwal’s Group of Eye Hospitals added, “The investment will be used to support the business through its next phase of growth, including the acquisition of small hospitals and chains as well as greenfield expansion of our networkand we will be deepening our presence in Kenya, Zambia, and Tanzania and look to add 10 centres across these countries.” Veda Corporate Advisors was the financial advisor to Dr Agarwal’s Health Care Ltd. on this transaction.